BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2782 related articles for article (PubMed ID: 776393)

  • 21. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [State of the stroma in melanoma in patients with different delayed hypersensitivity reaction to neoplasm antigen].
    Lavnikova GA; Voronina EA; Babakova SV
    Vopr Onkol; 1978; 24(11):24-30. PubMed ID: 741696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous delayed hypersensitivity reactions to soluble melanoma antigen in patients with ocular malignant melanoma.
    Char DH; Hollinshead A; Cogan DG; Ballintine EJ; Hogan MJ; Herberman RB
    N Engl J Med; 1974 Aug; 291(6):274-7. PubMed ID: 4407111
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
    Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
    J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigenic characterization of Mycobacterium bovis BCG culture filtrate.
    Gupta VK; Ram GC; Bansal MP
    Vet Microbiol; 1994 Aug; 41(4):345-53. PubMed ID: 7801534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of immunizing and delayed hypersensitivity eliciting antigens of Mycobacterium leprae, M. tuberculosis, M. vaccae, and M. bovis (BCG).
    Sinha S; Sreevatsa ; Gupta SK; Sengupta U
    Int J Lepr Other Mycobact Dis; 1987 Mar; 55(1):42-53. PubMed ID: 2435824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed cutaneous hypersensitivity reactions to concanavalin A-binding tumour membrane components.
    Cunningham TJ; Weber PB; Teitelbaum HD; Blumenstock FA; Charniga C
    Clin Exp Immunol; 1975 Jul; 21(1):97-100. PubMed ID: 1181077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of soluble melanoma cell membrane antigens in metastatic cells of various organs and further studies of antigens present in primary melanoma.
    Hollinshead AC
    Cancer; 1975 Oct; 36(4):1282-8. PubMed ID: 51680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunologic reactions in malignant melanoma of the skin in man].
    Veresova OV; Korosteleva TA
    Vopr Onkol; 1975; 21(4):74-80. PubMed ID: 1105967
    [No Abstract]   [Full Text] [Related]  

  • 30. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
    Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
    Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
    Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation of the level of humoral cytotoxins and delayed hypersensitivity skin reactions with survival of patients with melanoma of the skin].
    Korosteleva TA; Vagner RI; Veresova OV; Potapenkova LS
    Vopr Onkol; 1983; 29(4):38-40. PubMed ID: 6858049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
    Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
    Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cellular immunity in patients with melanoma].
    Gorodinova VV; Kholenshed A; Babakova SV
    Vopr Onkol; 1976; 22(12):3-5. PubMed ID: 1020253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin.
    Strohal R; Paucz L; Pehamberger H; Stingl G
    Cancer Res; 1994 Sep; 54(17):4734-9. PubMed ID: 8062272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
    Buckley CE; White DH; Seigler HF
    Monogr Allergy; 1977; 11():97-105. PubMed ID: 876133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo delayed hypersensitivity reactions to partially purified human melanoma antigens.
    Sutherland CM; Leong SP; Cooperband SR; Deckers PJ; Hornung MO; Krementz ET
    J Surg Oncol; 1982 Aug; 20(4):221-6. PubMed ID: 7109625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunopurification, characterization, and nature of membrane association of human melanoma-associated oncofetal antigen gp87 defined by monoclonal antibody 140.240.
    Liao SK; Kwong PC; Khosravi MJ
    J Cell Biochem; 1985; 27(3):303-16. PubMed ID: 3886678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody recognizing human melanoma-carcinoma cross-reacting oncofetal antigen epitopically associated with carcinoembryonic antigen.
    Liao SK; Kwong PC; Clarke BJ; Dent PB; Ryan ED; Khosravi MJ; Laferte S; Krantz MJ
    J Natl Cancer Inst; 1985 May; 74(5):1047-58. PubMed ID: 2582173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 140.